Harvard University (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
126
Publications
2451
Citations
105690
i10-index
802
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Sorafenib in Advanced Hepatocellular Carcinoma | 2008 | 12659 |
EASL Clinical Practice Guidelines: Management of h... | 2018 | 11069 |
Atezolizumab plus Bevacizumab in Unresectable Hepa... | 2020 | 6464 |
BCLC strategy for prognosis prediction and treatme... | 2021 | 3634 |
Simplified criteria for the diagnosis of autoimmun... | 2008 | 1808 |
Ramucirumab after sorafenib in patients with advan... | 2019 | 1593 |
Guidelines for the diagnosis and management of int... | 2014 | 1496 |
Updated efficacy and safety data from IMbrave150: ... | 2021 | 1397 |
Blockade of interleukin 6 trans signaling suppress... | 2000 | 1279 |
Tremelimumab plus Durvalumab in Unresectable Hepat... | 2022 | 1193 |
Peter R. Galle is a researcher with 2451 publications and 105690 citations. They are affiliated with Harvard University. Their research focuses on . With an h-index of 126, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Peter R. Galle and 250M+ other papers.
Citations per publication by year